Israel's Teva has acquired 19 percent of Clal Biotechnology Industries for $19 million and plans to participate in a joint $31 million investment in Clal with Clal's parent company. CBI is an investment company with R&D operations and stakes in Compugen, CureTech and other life sciences companies. Article